Sylvie Quaranta

<i><scp>UGT</scp>1A1</i> genotype and irinotecan therapy: general review and implementation in routine practice

Marie-Christine Étienne-Grimaldi, Jean‐Christophe Boyer, Fabienne Thomas et al. · Fundamental and Clinical Pharmacology · 2015 · 108 citations

Pathology, Pharmacotherapy, Advanced Colorectal Cancer +20

Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity

Romain Guilhaumou, Caroline Solas, Véronique Bourgarel‐Rey et al. · Cancer Chemotherapy and Pharmacology · 2011 · 49 citations

Intracellular Exposure, Medicine, Toxicology +7

Genetic polymorphism of the human cytochrome CYP2A13 in a French population: implication in lung cancer susceptibility

Christelle Cauffiez, Jean‐Marc Lo‐Guidice, Sylvie Quaranta et al. · Biochemical and Biophysical Research Communications · 2004 · 43 citations

Medicine, Genetics, Genetic Epidemiology +12

Validation of an Electrospray Ionization LC-MS/MS Method for Quantitative Analysis of Raltegravir, Etravirine, and 9 Other Antiretroviral Agents in Human Plasma Samples

Sylvie Quaranta, Christian Woloch, Alexandre Paccou et al. · Therapeutic Drug Monitoring · 2009 · 42 citations

Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV‐infected patients

Caroline Solas, Nicolas Simon, Marie‐Pierre Drogoul et al. · British Journal of Clinical Pharmacology · 2007 · 38 citations · Full text